3-year outcomes of men on AS in US community urology settings

To date we have seen very few data on the long-term follow-up of men in the US being initially managed on active surveillance (AS) after diagnosis with prostate cancer out in the “real world” of community urology practice. … READ MORE …

Patient satisfaction and the management of localized prostate cancer

A recent paper from a large Swedish research group has addressed patient satisfaction and the management of localized prostate cancer — with a specific, inclusive focus on the satisfaction of men initially managed on active surveillance. … READ MORE …

AS in practice in a specific US community setting

In a presentation at the ASCO annual meeting, Dr. Ronald Chen reported that just 32 percent of newly diagnosed men who were initially managed on active surveillance (AS) in North Carolina between 2011 and 2013 were actually managed in compliance with guideline recommended monitoring. … READ MORE …

Gallium-68 PSMA vs. fluorine-18 fluciclovine PET/CT scans

According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy. … READ MORE …

“If all you have is a hammer, everything looks like a nail”

It was called “instrument bias” by Abraham Maslow and Abraham Kaplan, but for present purposes, we’ll call it “specialty bias” — over-reliance on the tool one is most familiar with. … READ MORE …

Is whole pelvic radiation needed for primary treatment of Gleason 9/10 prostate cancer?

Whether whole pelvic radiation therapy (WPRT) is beneficial for men newly diagnosed with Gleason grade 9/10 (Grade Group 5) is controversial. … READ MORE …

UPDATE … the new PCa Social Network PLUS app

A couple of weeks ago (see here) we had first told you about the launch of the new PCa Social Network PLUS app that allows mobile access to a new social netowrk (and a clinical trial of its effects) for men with prostate cancer. … READ MORE …